Jefferies reiterates SFBC at buy

SFBC International was reiterated by Jefferies & Co. Inc. analyst David Windley at a buy rating with a $35 price target as Jefferies said it sees a tradable opportunity for investors as the stock rebounds from oversold levels on better understanding of the demand trends and mix of business issues influencing the third quarter. Demand for the company's services is robust, as generic bioequivalency is a driver of that demand and an area of emphasis for the company. Shares of the Miami pharmaceutical-services company were up 49 cents, or 1.54% at $32.31 on volume of 899,457 shares versus the three-month running average of 424,018 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.